Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care

OBJECTIVE — Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglita-zone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS — We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coro-nary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS — Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosigli-tazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-re-active protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 1.98 to 0.62 0.44 mg/l, P 0.001 vs. from 2.01 1.33 to 1.79 1.22 mg/l, P NS). However, the baseline and follow-up glucose and lipid concen-trations were not different between two groups. The rate of in-stent restenosis was significantly